# Progress Note 02 — Focused Visit (Intermediate follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Isaac Newton (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN011-SYN-TD
- Date: 1693-10-08
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rupert Okonkwo-Fairbanks, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Intermediate follow-up)

## Chief complaint

Ten-day review of metal and laboratory results; occupational and environmental medicine consultation today. **S**

## History of present illness

Mr. Newton returns ten days after his first visit. He has not entered the laboratory since then; the university safety office sealed it four days ago, after measuring mercury vapor, and removed the mercury and arsenic compounds. He has moved out of the rooms next to it. He has kept the sleep diary and a fixed rising time, sleeps about four hours, and has stopped working at night, but still dozes in his chair in the evening. He eats two small meals a day. He met by chance a friend to whom he had written an odd letter and asked him to pass on his apology; he says the ideas that friends were plotting against him now seem to him to have come out of exhaustion, though he still feels slighted by one colleague. He has had no thoughts of death, of harming himself, or of harming anyone. He saw Dr. Mbeki-Lindström of occupational and environmental medicine this morning. **S**

| Element | Detail |
|---|---|
| Exposure | None since intake; laboratory sealed; mercury vapor measured; chemicals removed |
| Sleep | About four hours; no night work; evening dozing continues |
| Appetite and weight | Two small meals a day; 63.8 kg, down 0.2 kg |
| Suspicious ideas | Largely given up; he attributes them to exhaustion and has apologized |
| Safety | No suicidal thoughts and no thoughts of harming others |
| PHQ-9 | 19, down from 20; item 9 scored 0 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Poor appetite; tired; no fever |
| Ears, nose, mouth, and throat | Negative | No bleeding gums, mouth ulcers, metallic taste, or excess salivation |
| Neurological | Negative | No tremor, numbness, tingling, or weakness; handwriting unchanged |
| Genitourinary | Negative | No frothy urine or swelling |
| Psychiatric | Positive | Low mood, loss of interest, poor concentration, early waking; no elevated mood, racing thoughts, or reduced need for sleep with high energy; no hallucinations |

5 systems reviewed. **S**

## Current medications

- Sertraline 50 mg oral tablet, one tablet by mouth each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/76 mmHg; pulse 80 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 63.8 kg; BMI 22.1 kg/m². All vital signs are synthetic.

PHQ-9: 19. All results are synthetic.

## Change since baseline

- PHQ-9: 20 at baseline, 19 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Thin, tired, neatly dressed |
| Mouth | Gums pink and firm; no gingivitis, stomatitis, or excess saliva |
| Neurological | No postural or intention tremor of the hands, eyelids, or lips; finger-nose and spiral drawing normal; handwriting steady; normal strength, reflexes, and sensation, including vibration at the toes |
| Mental status | Courteous and engaged; mood "low"; affect constricted; thought process linear; no fixed false beliefs; a residual sense of being slighted by a colleague, held with doubt; no hallucinations; no suicidal or homicidal ideation; insight good |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Major depressive disorder, single episode, severe, without psychotic features** (F32.2). A year of poor sleep and appetite with 4 kg weight loss, low mood, loss of interest, poor concentration, and suspicious ideas about friends, with PHQ-9 20 then 19. Hemoglobin 14.6 g/dL, sodium 140 mmol/L, creatinine 0.92 mg/dL (eGFR 101), glucose 88 mg/dL, calcium 9.5 mg/dL, albumin 4.2 g/dL, ALT 24 U/L, TSH 1.9 mIU/L, and vitamin B12 455 pg/mL are normal, and the MoCA was 27. The suspicious ideas were never fixed, are now largely retracted, and came with no hallucinations, so there are no psychotic features and the duration and conviction do not meet delusional disorder. No manic or hypomanic episode by interview. A mercury-induced depressive disorder was considered: the urine mercury is raised, but at 46 ug/L it is below the levels ATSDR links to irritability and depression, there is no tremor, gingivitis, or erethism, and his symptoms have followed the year-long course of a depressive episode, so mercury is at most a contributor and the primary diagnosis is a major depressive episode. Dr. Mbeki-Lindström agrees. **S**
   - Sertraline 50 mg each morning, starting today.
   - Weekly cognitive behavioral therapy with the clinic psychologist, starting next week.
   - Collaborative care: the clinic psychiatrist reviews his scores and safety each week.
   - Safety plan reviewed and unchanged; 988 Suicide & Crisis Lifeline and the clinic number confirmed.
   - If mood lifts quickly after removal from exposure alone, the diagnosis will be reconsidered.
2. **Raised urine mercury from occupational exposure** (R82.6). 24-hour urine mercury 46 ug/L (41 ug/g creatinine) and blood mercury 9.4 ug/L: real occupational absorption, in the band ATSDR links to subtle changes on nerve and psychomotor testing, without signs of toxicity. Blood lead 2.4 ug/dL is normal. Urine albumin-to-creatinine ratio 9 mg/g and creatinine are normal. The safety office measured mercury vapor of 0.08 mg/m3 at the furnace, above the NIOSH limit of 0.05 mg/m3 averaged over a work shift. **S**
   - No chelation and no provoked urine test, as Dr. Mbeki-Lindström advises.
   - Stay out of the laboratory until it is decontaminated, re-measured, and fitted with a fume hood.
   - Repeat 24-hour urine mercury and blood mercury in about three weeks, and again at three months with creatinine and urine albumin-to-creatinine ratio.
3. **Poor sleep, poor appetite, and suspicious thoughts** (R45.89). Explained by a major depressive episode with severe comorbid insomnia, with a possible small contribution from mercury exposure; superseded by those diagnoses. **S**
   - Managed under the depression, insomnia, and mercury problems.
4. **Chronic insomnia comorbid with depression** (G47.00). About four hours a night; evening dozing keeps the night sleep short. **S**
   - CBT-I: a sleep window of 12:30 to 5:30 am, no dozing in the evening chair, out of bed after 20 minutes awake; no hypnotics.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PHQ-9 | Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 19, down from 20; item 9 scored 0 |
| Survey | Suicide and violence risk reassessment (C-SSRS Since Last Visit, PHQ-9 item 9, and thoughts of harming others) | Every visit during active treatment | Completed today | No suicidal thoughts, intent, plan, or behavior; no thoughts of harming others. Protective factors unchanged; the laboratory's toxic chemicals have been removed |
| Laboratory | Workup for medical causes (blood count, metabolic panel, TSH, vitamin B12) | Once, at the initial depression workup | Completed today | Results from the first visit reviewed today: all normal |
| Survey | Bipolar screen at the initial workup | Once, at the initial depression workup | Completed today | No past manic or hypomanic episode on interview today; no Mood Disorder Questionnaire score is recorded |
| Laboratory | 24-hour urine mercury with creatinine correction, and blood mercury | At the exposure assessment, then 4 to 6 weeks after removal and at 3 months | Completed today | Results from the first visit reviewed today: urine 46 ug/L and 41 ug/g creatinine, blood 9.4 ug/L, all raised; blood lead 2.4 ug/dL, normal; repeat in about three weeks |
| Laboratory | Kidney function and urine protein (creatinine, eGFR, urine albumin-to-creatinine ratio) | At the exposure assessment and at 3 months | Completed today | Results from the first visit reviewed today: creatinine 0.92 mg/dL, eGFR 101, ratio 9 mg/g; dipstick protein negative |
| Examination | Signs of mercury toxicity: tremor (postural and intention), handwriting, gums and mouth, erethism, peripheral neuropathy | At the exposure assessment and at each follow-up while levels are raised | Completed today | No tremor, gingivitis, stomatitis, or neuropathy; no erethism beyond what his depression explains |
| Self-management | Removal from exposure and workplace hazard assessment | At once, then until the workplace is safe | Completed today | Laboratory sealed; mercury vapor 0.08 mg/m3 at the furnace (NIOSH limit 0.05 mg/m3 averaged over a shift; OSHA 0.1 mg/m3); chemicals removed; decontamination and a fume hood ordered |
| Medication safety | Chelation and provoked (chelator-challenge) urine testing | Only for symptomatic patients with high levels, decided with a medical toxicologist | Not indicated | Urine mercury below 100 ug/L with no tremor, gingivitis, or kidney injury; removal from exposure comes first, and provoked testing is not valid |
| Medication safety | SSRI tolerability check two weeks after starting | 2 weeks after starting and after each dose change | Due | Sertraline starts today |
| Referral | Occupational and environmental medicine (medical toxicology) consultation | For raised urine mercury with neuropsychiatric symptoms | Completed today | Seen today; chelation not indicated; return-to-work conditions set |
| Examination | Weight and nutrition | Every visit while weight is below his usual | Completed today | 63.8 kg, down 0.2 kg; two small meals a day |
| Self-management | Psychotherapy, sleep, and activity | Every visit during active treatment | Completed today | CBT booked; CBT-I sleep window set; walks most days |
| Laboratory | Lithium, anticonvulsant, or antipsychotic monitoring (levels, metabolic tests, AIMS) | Only on those drugs | Not indicated | Treated with an SSRI only; no antipsychotic, because there are no psychotic features |

## Goal progress

- Toxic and other medical causes assessed by the second visit. Outcome by 1693-10-08: Blood count, metabolic panel, TSH, vitamin B12, kidney tests, blood lead, and MoCA normal; blood and urine mercury raised from his work, below levels linked to overt toxicity. **S**
- No further exposure to mercury and other metals until the laboratory is made safe. In progress; target 1694-01-31. **S**
- Response (PHQ-9 down by at least 50 percent) by eight to twelve weeks of treatment, then remission (PHQ-9 below 5). In progress; target 1693-12-31. **S**
- No suicidal thoughts and no thoughts of harming others. In progress; target 1693-12-31. **S**
- At least six hours of sleep most nights without hypnotics. In progress; target 1693-12-31. **S**

## Medication changes

- Started: Sertraline 50 mg oral tablet, one tablet by mouth each morning **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge
- APA Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts (2019), American Psychological Association
- VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) (2022), American Psychiatric Association
- Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians (2016), American College of Physicians (Annals of Internal Medicine)
- Evaluating Mercury Exposure: Information for Health Care Providers (2018), Agency for Toxic Substances and Disease Registry
- NIOSH Pocket Guide to Chemical Hazards: Mercury compounds [except (organo) alkyls] (as Hg) (2026), National Institute for Occupational Safety and Health
- American College of Medical Toxicology Position Statement on Post-Chelator Challenge Urinary Metal Testing (2010), American College of Medical Toxicology (Journal of Medical Toxicology)
- Use and Misuse of Metal Chelation Therapy (McKay CA, editorial) and Recommendations for Provoked Challenge Urine Testing (Ruha AM), proceedings of the ACMT symposium (2013), American College of Medical Toxicology (Journal of Medical Toxicology)

## Follow-up

- Depression and exposure review in three weeks with a repeat 24-hour urine mercury; telephone contact sooner if needed. **S**
- Next scheduled visit 1693-10-22: preventive health visit at 50. **S**
